2025 年 4 月 24 日 一品红药业集团股份有限公司董事会 关于独立董事独立性情况的专项意见 一品红药业集团股份有限公司（以下简称"公司"）董事会现任两名独立董事 胡咸华先生、张克坚先生以及 2024 年度在任现已离任的两名独立董事陶剑虹女 士、杨德明先生，公司于近日收到上述独立董事提交的《独立董事独立性自查情 况表》，根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市 规则（2024 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作（2023 年 12 月修订）》等相关要求，公司董事会就在任独 立董事的独立性情况进行评估并出具如下专项意见： 根据公司独立董事自查及其在公司的履职情况，董事会认为公司报告期内任 职的独立董事张克坚、胡咸华、陶剑虹（已离任）、杨德明（已离任）均能够胜 任独立董事的职责要求，其未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在妨碍独立董事进 行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独 立董事管理办法》等法律法规及《公司章程》中关于独立董事的任职资格 ...

一品红药业集团股份有限公司 独立董事 2024 年度述职报告 （张克坚） 尊敬的各位股东及股东代表： 作为一品红药业集团股份有限公司（以下简称"公司"）第四届董事会的独 立董事，本人严格按照《公司法》《上市公司独立董事管理办法》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文 件以及《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行 独立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表意见，充分发挥独立董事的独立性和专业性作用， 及时了解公司的生产经营信息，全面关注公司的发展状况，促进公司规范运作， 切实维护公司和全体股东特别是中小股东的合法权益。 2024 年 7 月，公司召开第三届董事会二十四次会议、2024 年第二次临时股 东大会，选举本人担任公司第四届董事会独立董事及各专门委员会委员，现将 2024 年度履行职责的情况报告如下： 一、独立董事基本情况 2024 年度，本人积极参加公司召开的董事会和股东大会，认真审阅会议资 料，积极参与各项议案的讨论并提出合理化建议，为董事会科学决策发挥了应有 的作 ...

一品红药业集团股份有限公司 独立董事 2024 年度述职报告 2024 年 7 月，本人任期届满，不再担任公司董事会独立董事及董事会专门 委员会相关职务，现将本人 2024 年度履行独立董事职责的情况汇报如下： 一、独立董事基本情况 本人陶剑虹，女，中国国籍，无境外永久居留权，1958 年出生，博士学历， 现任广西柳药集团股份有限公司、科兴生物制药股份有限公司和广州市香雪制药 股份有限公司独立董事，历任一品红药业集团股份有限公司独立董事。 2024 年任职期间，本人任职符合法律法规和规范性文件等规定的独立性要 求，不存在影响独立性的情况。 二、年度履职情况 （一）出席董事会、股东大会情况 2024 年，本人出席董事会、列席股东大会的情况如下： | 独立董事 | 报告期应 | 现场出席 | 以通讯方 | 委托出席 | 缺席董事 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 参加董事 | 董事会 | 式参加董 | 董事会 | 会次数 | 大会次数 | | | 会次数 | 次数 | 事会次数 | 次数 | | | | 陶剑虹 | 4 | 4 ...

一品红药业集团股份有限公司 独立董事 2024 年度述职报告 （杨德明已离任） 尊敬的各位股东及股东代表： 本人作为一品红药业集团股份有限公司（以下简称"公司"）第三届董事会 的独立董事，严格按照《公司法》《上市公司独立董事管理办法》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文 件以及《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行 独立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表意见，充分发挥独立董事的独立性和专业性作用， 及时了解公司的生产经营信息，全面关注公司的发展状况，促进公司规范运作， 切实维护公司和全体股东特别是中小股东的合法权益。 2024 年 7 月，本人任期届满，不再担任公司董事会独立董事及董事会专门 委员会相关职务，现将本人 2024 年度履行独立董事职责的情况汇报如下： 一、独立董事基本情况 本人杨德明，男，中国国籍，无境外永久居留权，1975 年出生，博士学历， 现任暨南大学教授、博士生导师，兼任广东开平农村商业银行股份有限公司独立 董事（非上市公司）和广东芳源环保股份有 ...

一品红药业集团股份有限公司 独立董事 2024 年度述职报告 （胡咸华） 尊敬的各位股东及股东代表： 二、年度履职情况 （一）出席董事会、股东大会情况 2024 年，本人出席董事会、股东大会的情况如下： | 独立董事 | 报告期应 | 现场出席 | 以通讯方 | 委托出席 | 缺席董事 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 参加董事 | 董事会 | 式参加董 | 董事会 | 会次数 | 大会次数 | | | 会次数 | 次数 | 事会次数 | 次数 | | | | 胡咸华 | 5 | 5 | 0 | 0 | 0 | 3 | 作为一品红药业集团股份有限公司（以下简称"公司"）第四届董事会的独 立董事，本人严格按照《公司法》《上市公司独立董事管理办法》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文 件以及《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行 独立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表意见，充分发挥独立董 ...

| 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 广东广润集团有限公司 | 18360.00 | 43.96 | 不变 | | 吴美容 | 2548.66 | 6.10 | 不变 | | 广州市福泽投资管理中心(有限合伙) | 2430.00 | 5.82 | 不变 | | 吴春江 | 2177.88 | 5.21 | 不变 | | 陈丹娜 | 908.28 | 2.17 | 不变 | | 李捍雄 | 621.00 | 1.49 | 新进 | | 中国工商银行股份有限公司-广发多因子灵活配混合型 证券投资基金 | 596.30 | 1.43 | 新进 | | 一品红（300723）药业股份有限公司-2024年员工持股 | | | | | 计划 | 511.61 | 1.22 | 新进 | | 广州南沙阳光金瑞投资有限公司 | 487.02 | 1.17 | -29.92 | | 全国社保基金五零三组合 | 400.00 | 0.96 | 新进 | | 较上个报告期退出前十大股东有 | | | | | ...

Financial Performance - The company's operating revenue for 2024 was ¥1,450,230,295.28, a decrease of 42.07% compared to ¥2,503,447,004.47 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥540,038,956.70, representing a decline of 392.52% from ¥184,613,302.81 in 2023[23]. - The cash flow from operating activities for 2024 was -¥550,424,562.17, a decrease of 220.17% compared to ¥458,051,312.80 in 2023[23]. - The basic earnings per share for 2024 was -¥1.1956, down 392.54% from ¥0.4087 in 2023[23]. - The total assets at the end of 2024 were ¥4,404,103,484.82, a slight decrease of 0.03% from ¥4,405,295,590.95 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were ¥1,878,454,901.15, down 25.52% from ¥2,522,087,479.40 at the end of 2023[23]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which was -¥288,936,321.54 for 2024 compared to ¥119,978,271.81 in 2023, a drop of 340.82%[23]. - The company's revenue after deducting unrelated business income for 2024 was ¥1,418,927,617.26, compared to ¥2,480,622,403.37 in 2023[23]. - The company achieved a revenue of 145,023.03 million yuan, a year-on-year decrease of 42.07%[55]. - The net profit attributable to shareholders was CNY -540.04 million, a year-on-year decline of 392.52%[55]. Research and Development - The company has increased its investment in research and development, with R&D expenses accounting for over 20% of revenue. The innovative drug AR882 has entered the Phase III clinical stage domestically and internationally[4]. - The company is committed to enhancing its innovative drug development capabilities through various mechanisms, including independent and collaborative research[5]. - The company has a total of 15 innovative drugs in its R&D pipeline, including AR882 for hyperuricemia and APH01727 for diabetes and weight loss, both currently in clinical trials[45]. - The company has established a complete R&D system for chronic disease drugs, with 29 ongoing projects, including global innovative drugs AR882 and APH01727, and holds 65 registered chronic disease drug approvals[52]. - The company has established multiple specialized R&D centers, including those for innovative drugs and high-end generics, enhancing its innovation capabilities[68]. - The company has a dedicated R&D team of 338 personnel, supported by a global network of scientific advisors to enhance innovation[73]. - The company has implemented a digital management platform for R&D, which has won the 2023 National Pharmaceutical Industry Excellent Digital Case Award[92]. - The company has 71 ongoing research projects based on its R&D technology platform, excluding technology transformation projects[93]. - The company has initiated clinical trials for new chronic disease medications, such as AR882 capsules and APH01727 tablets, indicating a commitment to innovation in this sector[129]. Market and Product Development - The company is focused on the development of innovative drugs and children's medications, aligning with the growing demand for high-quality healthcare solutions in the market[32]. - In 2024, the company's revenue from pediatric drugs reached 936 million yuan, accounting for 66.71% of its pharmaceutical manufacturing business revenue[40]. - The company holds a total of 26 pediatric drug registration approvals as of the report date[40]. - The company generated 370 million yuan in revenue from chronic disease drugs in 2024, representing 26.36% of its pharmaceutical manufacturing business revenue[42]. - The number of approved pediatric drugs increased significantly, with 106 new varieties approved during the reporting period, including 20 (18.9%) that expedited through priority review[37]. - The company has 65 registered products in the chronic disease drug category as of the report date[42]. - The pediatric drug market is expected to experience rapid growth due to increased government support and a focus on suitable formulations for children[40]. - The company is actively expanding its sales channels, including new retail channels such as chain KA and internet marketing[67]. - The company has received production approval for multiple new products, including APRD-H162 and APRD-H186, expanding its product categories in both chronic and pediatric medications[128]. Regulatory and Compliance - The company emphasizes strict adherence to GMP and GSP requirements in its production and distribution processes to ensure product quality[7]. - The company has maintained a good track record in product quality, with no major quality incidents reported, but acknowledges potential risks as it expands its operational scale[7]. - The company is closely monitoring industry policy changes that may impact its operational model and competitive landscape, leveraging its full industry chain layout to respond proactively[170]. - The company has not engaged in any securities or derivative investments during the reporting period[146][147]. - The company has not provided guarantees for its controlling shareholders, ensuring no misuse of company funds[177]. Governance and Management - The company emphasizes a governance structure that ensures effective checks and balances among shareholders, the board, and management, promoting transparency and shareholder rights[176]. - The company has established four specialized committees under the board, with independent directors constituting two-thirds of the members in each committee, enhancing decision-making quality[178]. - The company respects and protects the rights of stakeholders, focusing on social responsibility and communication[179]. - The company has a structured remuneration policy that considers operational performance and individual capabilities[191]. - The board of directors consists of 5 members, including 2 independent directors, complying with legal and regulatory requirements[178]. - The company has conducted multiple shareholder meetings in 2024, with participation rates ranging from 59.98% to 66.69%[181]. - The company is preparing for a governance transition with upcoming elections for board and supervisory roles scheduled for July 18, 2024[183]. Strategic Focus - The company aims to enhance its innovation capabilities by focusing on children's medication and chronic disease treatments, leveraging advanced drug development technologies[160]. - The company plans to optimize its innovation system and R&D platforms to strengthen its core competitiveness, with a focus on key projects like AR882 and APH01727[164]. - The company plans to enhance its digital operations through projects like SAP digital operation and WMS automation, aiming for efficient and intelligent management[105]. - The company is actively investing in research and technology services, with a focus on strategic emerging industries[156]. - The company aims to expand its market share through mergers and acquisitions in the pharmaceutical and biotechnology sectors[156].

Financial Performance - The company's revenue for Q1 2025 was ¥376,961,180.39, a decrease of 39.48% compared to the same period last year[5] - Net profit attributable to shareholders was ¥56,588,459.64, down 43.70% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥15,189,437.34, reflecting an 84.50% decline compared to the previous year[5] - Total revenue for Q1 2025 was $376.96 million, a decrease of 39.48% compared to $622.87 million in Q1 2024, primarily due to market conditions[13] - Net profit for the current period is ¥53,446,158.72, a decline of 44.1% from ¥95,487,011.59 in the previous period[29] - The basic and diluted earnings per share decreased to ¥0.1253 from ¥0.2225 in the previous period, reflecting a decline of 43.7%[30] Research and Development - The company invested ¥74,228,100 in R&D, which is an increase of 18.71% year-on-year, focusing on the AR882 Phase III clinical trial[10] - R&D expenses decreased by 41.40% to $36.64 million from $62.53 million, attributed to the optimization of generic drug projects and capitalization of clinical costs for innovative drug AR882[13] Assets and Liabilities - The total assets increased by 19.11% to ¥5,245,752,699.90 compared to the end of the previous year[5] - The company's total liabilities increased to ¥3,256,418,795.46, up 31.9% from ¥2,468,215,739.10 in the previous period[27] - Long-term borrowings rose by 104.69% to ¥1,248,600,000, primarily due to increased bank loans[11] - Long-term borrowings rose significantly to ¥1,248,600,000.00, compared to ¥610,000,000.00 in the previous period, indicating a 104.1% increase[27] Cash Flow - The cash flow from operating activities was ¥38,342,797.32, a decrease of 29.28% from the same period last year[5] - Cash flow from operating activities netted $38.34 million, down 29.28% from $54.22 million, mainly due to declining revenue[14] - Cash received from government subsidies rose by 864.53% to $83.09 million from $8.61 million, reflecting increased government support[14] - Cash and cash equivalents increased by 629.86% to $200.42 million from a decrease of $37.82 million in the previous year[14] - Net cash flow from operating activities was $38,342,797.32, a decrease from $54,218,604.87 in the previous period[33] - Cash inflow from investment activities totaled $403,368,522.95, compared to $188,217,619.36 previously[33] - Net cash flow from financing activities was $808,328,229.49, up from $362,586,721.55 in the prior period[34] Investment and Income - Investment income increased significantly by 3,529.23% to $26.54 million from $731,403.95, driven by higher profits from associated companies[13] - The company reported a significant increase in non-operating income, which rose by 28,951.33% to $50.35 million from $173,297.87, mainly from government subsidies[13] - The company reported a significant increase in investment income to ¥26,544,308.36, compared to ¥731,403.95 in the previous period[29] Operational Metrics - The sales expense ratio for the reporting period was 34.06%, indicating a focus on optimizing the marketing system[9] - Sales expenses decreased by 40.59% to $128.40 million from $216.11 million, mainly due to reduced promotional activities[13] - The company reported a decrease in cash received from sales of goods and services to ¥251,950,744.34, down 65.1% from ¥721,960,355.96 in the previous period[32] Shareholder Information - The total equity attributable to shareholders of the parent company is ¥1,935,043,360.79, an increase of 3.0% from ¥1,878,454,901.15 in the previous period[27] - The company completed the registration of its 2025 stock option incentive plan, which was approved by the board and shareholders[22] - The company has a total of 34,042,876.0 shares under lock-up agreements, with 20,000 shares released during the current period[20] Government Support - The company received a government subsidy of 50 million yuan for its wholly-owned subsidiary, Guangdong Zerui Pharmaceutical Co., Ltd.[23]

一品红：AR882全球III期临床进展顺利，有望抢占痛风治疗市场 金十数据4月23日讯，一品红宣布其在研全球1类创新药AR882全球III期临床快速进展，目前全球已入组 上千人。AR882是去年美国食品药品监督管理局授予给中国企业快速通道资格中唯一非肿瘤类药物，用 于痛风石研究，有望填补痛风石治疗领域口服药物的全球空白。 ...

证券研究报告|公司动态点评 2025 年 04 月 21 日 一品红（300723.SZ） AR882 全球 III 期临床稳步推进，BIC 药物潜力凸显 | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 2027E 增持（首次评级） | | | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,280 | 2,503 | 1,618 | 1,973 | 2,251 | 股票信息 | | | 增长率 yoy（%） | 3.7 | 9.8 | -35.4 | 21.9 | 14.1 | | | | 归母净利润（百万元） | 291 | 185 | -575 | 262 | 360 | 行业 | 医药 | | 增长率 yoy（%） | -5.3 | -36.5 | - | 145.6 | 37.4 | 2025 年 4 月 18 日收盘价（元） | 36.95 | | ROE（%） | 12.1 | 5.8 | -27.1 | 10.9 | 13.1 | 总市值（百万元） | 16,690 ...